Home > Neurology > MTIS 2020 > Contents > Injection-site reactions with galcanezumab are mild and self-limiting

Injection-site reactions with galcanezumab are mild and self-limiting

Presented By
Dr V.L. Stauffer
Conference
MTIS 2020
Trial
Phase 3, CONQUER
Injection-site reactions, most commonly pain and erythema, may occur with galcanezumab. This finding of the CONQUER trial is consistent with the overall safety profile of galcanezumab. Only one patient discontinued due to injection site erythema. No serious adverse events (AEs) related to injection sites were reported [1]. In previous phase 3 galcanezumab studies, injection-site reactions were the most frequently reported treatment-emergent AEs. In the CONQUER study, galcanezumab-treated patients received a 240 mg loading dose of galcanezumab followed by 120 mg per month. Patients were treated for up to 6 months with galcanezumab: 3 months double-blind period and 3 months during the open-label period. The mean age was 45.8 years, and the majority were female (85.9%) and White (81.7%). At baseline, patients had on average 13.2 migraine headache days per m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on